Patents Represented by Attorney Marshall, O'Toole et al.

Find this attorney in the Justia Lawyer Directory

  • Recombinant lectins
    Patent number: 5840522
    Abstract: DNA sequences encoding full length precursor proteins, which proteins contain both A and B portions of two ricin isotoxins and ricin agglutinin, as well as the linker regions have been determined. These DNAs or portions or modifications thereof are expressed in recombinant hosts to obtain the desired proteins or proteins which can readily converted thereto. One of the ricin isotoxins may be related to ricin E.
    Type: Grant
    Filed: May 9, 1995
    Date of Patent: November 24, 1998
    Assignee: Chiron Corporation
    Inventor: Michael Piatak, Jr.
  • Native type II GAP, methods for purifying various GAPs and uses of GAPs to diagnose cancer
    Patent number: 5830684
    Abstract: Native Type II GAP (GTPase activating protein), its uses in cancer diagnosis, and methods for obtaining and purifying native and recombinant Types I and II GAPs are described.
    Type: Grant
    Filed: December 7, 1990
    Date of Patent: November 3, 1998
    Assignee: Chiron Corporation
    Inventors: Robert Halenbeck, Kirston Koths, Francis P. McCormick, Bonnee Rubinfeld, Edward C. O'Rourke, Robin Clark, Gail L. Wong, George Martin
  • Purified human CSF-1
    Patent number: 5792450
    Abstract: The present invention relates to the purification of proteins, to the products of such purification, and to DNA probes constructed therefrom. More specifically, the invention relates to the purification and sequencing of murine and human colony stimulating factor-1 (CSF-1).
    Type: Grant
    Filed: March 13, 1995
    Date of Patent: August 11, 1998
    Assignees: Chiron Corporation, Albert Einstein College of Medicine
    Inventors: Kenneth J. Wilson, E. Richard Stanley, Albert Boosman, Mary Kim Warren, James E. Strickler, Judit Csejtey
  • Gap gene sequences
    Patent number: 5760203
    Abstract: Guanosine triphosphatase activating protein (GAP) DNA sequences are described that are useful as cancer diagnostics, particularly to detect cancer cells that express the ras oncogene protein p21 by measuring the level of GAP gene expression or amplification.
    Type: Grant
    Filed: February 2, 1994
    Date of Patent: June 2, 1998
    Assignee: Chiron Corporation
    Inventors: Gail L. Wong, George Martin, Francis P. McCormick, Bonnee Rubinfeld, Edward C. O'Rourke, Robin Clark
  • Use of CSF-1 to treat tumor burden
    Patent number: 5725850
    Abstract: A colony stimulating factor, CSF-1, is a lymphokine useful in treating or preventing bacterial, viral or fungal infections, neoplasms, leukopenia, wounds, and in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein.
    Type: Grant
    Filed: January 11, 1995
    Date of Patent: March 10, 1998
    Assignee: Chiron Corporation
    Inventors: Peter Ralph, Kong T. Chong, James Devlin, Robert Zimmerman, Sharon Lea Aukerman, David B. Ring, Sylvia Hsieh Ma